Perspective Therapeutics (CATX) News Today $2.85 +0.01 (+0.35%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Perspective Therapeutics: Definitely Not Looking Overvalued NowDecember 20 at 5:03 PM | seekingalpha.comCharles Schwab Investment Management Inc. Acquires 298,778 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Charles Schwab Investment Management Inc. grew its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 221.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 433,522 shares of the companDecember 13, 2024 | marketbeat.comWalleye Capital LLC Sells 494,706 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Walleye Capital LLC cut its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 96.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,117 shares of the company's stock after selling 494,706 shares during the qDecember 11, 2024 | marketbeat.comPerspective Therapeutics management to meet with TruistDecember 10, 2024 | markets.businessinsider.comInsider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) Director Purchases 25,975 Shares of StockDecember 7, 2024 | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) Director Acquires $100,003.75 in StockPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) Director Heidi Henson purchased 25,975 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The stock was bought at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the purchase, the director now owns 25,975 shares in the company, valued at $100,003.75. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.December 6, 2024 | marketbeat.comJanus Henderson Group PLC Boosts Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)Janus Henderson Group PLC grew its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 8.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,799,352 shares of the company's stock after purchDecember 6, 2024 | marketbeat.comFmr LLC Has $73.49 Million Stake in Perspective Therapeutics, Inc. (NYSE:CATX)Fmr LLC raised its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 3,994.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,504,822 shares of the company's stock after buying an additional 5,370,392 shDecember 6, 2024 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 8,000 SharesDecember 5, 2024 | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and eightNovember 30, 2024 | marketbeat.comRobert F. Williamson III Buys 6,266 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockNovember 28, 2024 | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt Acquires 12,829 SharesPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CFO Jonathan Robert Hunt purchased 12,829 shares of the stock in a transaction on Monday, November 25th. The shares were acquired at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the transaction, the chief financial officer now owns 48,800 shares of the company's stock, valued at approximately $186,416. The trade was a 35.66 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.November 27, 2024 | marketbeat.comPerspective Therapeutics, Inc. to Present at Upcoming Investor Conferences in New York and FloridaNovember 27, 2024 | quiverquant.comPerspective Therapeutics to Participate in Upcoming Investor Conferences in DecemberNovember 27, 2024 | globenewswire.comInsider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CEO Buys 14,500 Shares of StockNovember 27, 2024 | insidertrades.comJohan M. Spoor Purchases 14,500 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CEO Johan M. Spoor bought 14,500 shares of Perspective Therapeutics stock in a transaction dated Monday, November 25th. The shares were acquired at an average price of $3.78 per share, with a total value of $54,810.00. Following the completion of the purchase, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This trade represents a 10.54 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.November 26, 2024 | marketbeat.comPerspective Therapeutics downgraded to Neutral from Buy at BofANovember 26, 2024 | markets.businessinsider.comCautious Hold Rating for Perspective Therapeutics Amid Efficacy and Safety ConcernsNovember 26, 2024 | markets.businessinsider.comB of A Securities Downgrades Perspective Therapeutics (CATX)November 26, 2024 | msn.comBank of America Downgrades Perspective Therapeutics (NYSE:CATX) to NeutralBank of America downgraded shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $24.00 to $5.00 in a research report on Monday.November 25, 2024 | marketbeat.comPerspective Therapeutics selloff a buying opportunity, says JonesResearchNovember 23, 2024 | msn.comTruist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)November 22, 2024 | markets.businessinsider.comPerspective Therapeutics price target lowered to $16 from $22 at OppenheimerNovember 22, 2024 | markets.businessinsider.comPerspective Therapeutics (NYSE:CATX) Given New $16.00 Price Target at OppenheimerOppenheimer lowered their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a report on Friday.November 22, 2024 | marketbeat.comPerspective Therapeutics to pursue dose escalation in Phase 1/2a clinical trialNovember 22, 2024 | markets.businessinsider.comPerspective slips after Phase 1/2 trial data for radio pharma drugNovember 22, 2024 | msn.comPerspective Therapeutics, Inc. Reports Positive Initial Results from Phase 1/2a Trial of [212Pb]VMT-α-NET for Neuroendocrine TumorsNovember 21, 2024 | quiverquant.comPerspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical SymposiumNovember 21, 2024 | globenewswire.comPerspective Therapeutics (CATX) Receives a Buy from RBC CapitalNovember 20, 2024 | markets.businessinsider.comCATX FY2024 EPS Estimate Boosted by Cantor FitzgeraldPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of Perspective Therapeutics in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the cNovember 18, 2024 | marketbeat.comPerspective Therapeutics, Inc. to Present Initial Results of [212Pb]VMT-α-NET Phase 1/2a Trial at NANETS SymposiumNovember 15, 2024 | quiverquant.comPerspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024November 15, 2024 | globenewswire.comOptimistic Outlook for Perspective Therapeutics Amid Promising Trial DevelopmentsNovember 14, 2024 | markets.businessinsider.comPerspective Therapeutics Reports Strong Cash Position and Clinical AdvancesNovember 14, 2024 | markets.businessinsider.comBuy Rating for Perspective Therapeutics Due to Clinical Progress and Strategic Manufacturing ExpansionNovember 13, 2024 | markets.businessinsider.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 ResultsNovember 12, 2024 | globenewswire.comPerspective Therapeutics Q3 2024 Earnings PreviewNovember 12, 2024 | msn.comWealthPlan Investment Management LLC Invests $4.53 Million in Perspective Therapeutics, Inc. (NYSE:CATX)WealthPlan Investment Management LLC bought a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 339,292 shares of the company's stock, vaNovember 12, 2024 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of "Buy" from AnalystsPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has been assigned a consensus rating of "Buy" from the ten ratings firms that are covering the company, MarketBeat reports. Ten research analysts have rated the stock with a buy recommendation. The average 12 month price target among broNovember 5, 2024 | marketbeat.comHills Bank & Trust Co Invests $13.72 Million in Perspective Therapeutics, Inc. (NYSE:CATX)Hills Bank & Trust Co bought a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,027,830 shares of the company's stock,November 1, 2024 | marketbeat.comPerspective Therapeutics (AMEX:CATX) Stock, Short Interest ReportNovember 1, 2024 | benzinga.comPerspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial ResultsNovember 1, 2024 | markets.businessinsider.comPerspective Therapeutics to Participate in Upcoming Investor Conferences in NovemberOctober 29, 2024 | globenewswire.comPerspective Therapeutics initiated with a Buy at UBSOctober 25, 2024 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Perspective Therapeutics (CATX)October 25, 2024 | markets.businessinsider.comNicholson Wealth Management Group LLC Acquires New Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)Nicholson Wealth Management Group LLC purchased a new position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,602,283 sOctober 25, 2024 | marketbeat.comUBS Initiates Coverage of Perspective Therapeutics (CATX) with Buy RecommendationOctober 24, 2024 | msn.comPerspective Therapeutics (NYSE:CATX) Shares Gap Up - Here's What HappenedPerspective Therapeutics (NYSE:CATX) Shares Gap Up - Here's WhyOctober 24, 2024 | marketbeat.comPerspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from WedbushWedbush reissued an "outperform" rating and issued a $20.00 price target on shares of Perspective Therapeutics in a report on Thursday.October 24, 2024 | marketbeat.comUBS Group Begins Coverage on Perspective Therapeutics (NYSE:CATX)UBS Group began coverage on shares of Perspective Therapeutics in a research note on Thursday. They issued a "buy" rating and a $20.00 price objective for the company.October 24, 2024 | marketbeat.com Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street Icon: “You must get on the right side of this thing” (Ad)I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years. This market shakeup is going to be much more intense. CATX Media Mentions By Week CATX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CATX News Sentiment▼0.800.59▲Average Medical News Sentiment CATX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CATX Articles This Week▼14▲CATX Articles Average Week Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LQDA News BVS News EYE News FNA News AVNS News BFLY News IRMD News AXGN News SMLR News SIBN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CATX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
